Market Challenges And Opportunities

The global fascioliasis market's growth can be hindered by lack of standardization of diagnostic testing and treatment alternatives for the prevention and control of fascioliasis. Triclabendazole is the only U.S. FDA approved drug for the treatment of fascioliasis. For instance, in February 2022, Novartis AG, a pharmaceutical company, announced that they had started a phase IV, multi center, open label study to determine the safety and tolerability and clinical outcome of triclabendazole in 6 years of age or older patients with fascioliasis. The trial is expected to be completed in March 2026.

Global Fascioliasis Market – Driver

Ongoing research and development by key market players

Ongoing research and development by key market players is expected to drive the fascioliasis market over the forecast period. For instance, in July 2020, Romark, L.C., a pharmaceutical company, announced that they had started a clinical trial on Nitazoxanide to evaluate the safety and efficacy of nitazoxanide in the treatment of mild or moderate COVID-19.

Global Fascioliasis Market: Restraint

Lack of standardization of diagnostic testing and treatment alternatives for the prevention and control of fascioliasis to hinder the market.

Lack of treatment alteratives for fascioliasis is expected to hinder the global fascioliasis market growth over the forecast period. For instance, in November 2020, according to data published by National Center for Biotechnology Information, as Fascioliasis is an emerging infection around the world with an uncertain burden, lack of standardization of diagnostic testing and treatment alternatives for the control and treatment of fascioliasis which hindered the global fascioliasis market over the forecast period.